What is HC Wainwright’s Forecast for INO Q1 Earnings?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for Inovio Pharmaceuticals in a research note issued on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will earn ($0.44) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $3.00 target price on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.31) EPS and FY2026 earnings at ($1.47) EPS.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.23. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.01 million.

Several other research firms also recently commented on INO. StockNews.com downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 12th. Royal Bank of Canada reissued a “sector perform” rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday. Finally, Oppenheimer lowered their target price on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $9.75.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $2.05 on Thursday. The firm has a market cap of $75.18 million, a price-to-earnings ratio of -0.64 and a beta of 1.40. The stock’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $2.50. Inovio Pharmaceuticals has a one year low of $1.42 and a one year high of $12.62.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of INO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares during the period. AQR Capital Management LLC bought a new position in Inovio Pharmaceuticals in the first quarter valued at approximately $120,000. Nomura Holdings Inc. bought a new position in Inovio Pharmaceuticals in the first quarter valued at approximately $28,000. Freedom Investment Management Inc. acquired a new position in Inovio Pharmaceuticals during the first quarter valued at approximately $31,000. Finally, Nuveen LLC bought a new stake in Inovio Pharmaceuticals during the first quarter worth $168,000. Institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.